Prognostic value of SUVmax measured by F-18 FDG PET/CT in patients with primary gastric lymphoma

433 Objectives The aim of this retrospective study was to determine whether glucose metabolism assessed by F-18 FDG PET/CT provides prognostic information independent of established prognostic factors in patients with gastric lymphoma. Methods We reviewed retrospectively the medical records of 86 patients (men 42, women 44, mean age 58 years) with pathologic proven gastric lymphoma (34 mucosa-associated lymphoid tissue[MALT], 52 aggressive non-Hodgkin’s lymphoma[AGNHL]) They underwent F-18 FDG PET/CT as part of a pretreatment workup from February 2004 to July 2012. For the analysis, patients were classified by age, sex, stage, serum LDH, International Prognostic Index(IPI)score, extranodal spread, FDG avidity and intensity (visual assessment and SUVmax). The relationship between FDG uptake and survival was analyzed using the Kaplan-Meier with log-Rank test and Cox’s proportional-hazard regression methods. Results Median survival for all 86 study subjects was 1117 days and median SUV by PET/CT was 6.1 (range:1.9-32.7). Patients with SUVmax of ≤6.1 survived significantly longer than patients with SUVmax of >6.1 ( Median 1146 vs.1081 days, p=0.009) The survival was also found to be significantly related to age (p=0.0002), histologic type (p=0.004), extranodal spread (p=0.0004), IPI score (p Conclusions Higher SUVmax on pretreatment F-18 FDG PET/CT can predict poorer survival in patients with gastric lymphoma.